British Journal of Radiology

New agents in clinical oncology
pp. S1-S1(1)
Author: WILLIAMS, K

PARP inhibitors and cancer therapy — early results and potential applications
pp. S2-S5(4)
Authors: Jones, C; Plummer, E R

Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer
pp. S6-S11(6)
Authors: Kyle, S; Thomas, H D; Mitchell, J; Curtin, N J

Tumour vascular disrupting agents: combating treatment resistance
pp. S12-S20(9)
Authors: Tozer, G M; Kanthou, C; Lewis, G; Prise, V E; Vojnovic, B; Hill, S A

Inhibition of vascular endothelial growth factor signalling using cediranib (RECENTIN^TM; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts
pp. S21-S27(7)
Authors: Williams, K J; Telfer, B A; Shannon, A M; Babur, M; Stratford, I J; Wedge, S R

Experimental treatment of neuroblastoma using [¹³¹I]meta-iodobenzylguanidine and topotecan in combination
pp. S28-S35(8)
Authors: McCluskey, A G; Boyd, M; Pimlott, S L; Babich, J W; Gaze, M N; Mairs, R J

Epidermal growth factor receptor-targeted therapy
pp. S36-S44(9)
Authors: WEST, C M; JOSEPH, L; BHANA, S

Gene therapy approaches to enhance bioreductive drug treatment
pp. S45-S56(12)
Authors: Cowen, R L; Garside, E J; Fitzpatrick, B; Papadopoulou, M V; Williams, K J

The thioredoxin system: a key target in tumour and endothelial cells
pp. S57-S68(12)
Authors: Mukherjee, A; Martin, S G

A proteomic approach to identifying new drug targets (potentiating topoisomerase II poisons)
pp. S69-S77(9)
Author: JENKINS, J R